NZ514661A - alpha-substituted carboxylic acid derivatives and their use as therapeutic agents in pharmaceutical compositions - Google Patents

alpha-substituted carboxylic acid derivatives and their use as therapeutic agents in pharmaceutical compositions

Info

Publication number
NZ514661A
NZ514661A NZ514661A NZ51466100A NZ514661A NZ 514661 A NZ514661 A NZ 514661A NZ 514661 A NZ514661 A NZ 514661A NZ 51466100 A NZ51466100 A NZ 51466100A NZ 514661 A NZ514661 A NZ 514661A
Authority
NZ
New Zealand
Prior art keywords
carboxylic acid
acid derivatives
activity
substituted carboxylic
therapeutic agents
Prior art date
Application number
NZ514661A
Other languages
English (en)
Inventor
Takashi Fujita
Kunio Wada
Hidehito Honma
Toshihiko Fujiwara
Haruo Iwabuchi
Minoru Oguchi
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of NZ514661A publication Critical patent/NZ514661A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NZ514661A 1999-04-06 2000-04-06 alpha-substituted carboxylic acid derivatives and their use as therapeutic agents in pharmaceutical compositions NZ514661A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP9928699 1999-04-06
JP21514199 1999-07-29
PCT/JP2000/002215 WO2000059889A1 (en) 1999-04-06 2000-04-06 α-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES

Publications (1)

Publication Number Publication Date
NZ514661A true NZ514661A (en) 2003-06-30

Family

ID=26440432

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ514661A NZ514661A (en) 1999-04-06 2000-04-06 alpha-substituted carboxylic acid derivatives and their use as therapeutic agents in pharmaceutical compositions

Country Status (18)

Country Link
US (2) US6596751B2 (ko)
EP (1) EP1167357A4 (ko)
KR (1) KR20020060067A (ko)
CN (1) CN1208323C (ko)
AU (1) AU760163B2 (ko)
BR (1) BR0009593A (ko)
CA (1) CA2369871A1 (ko)
CZ (1) CZ20013593A3 (ko)
HK (1) HK1039939A1 (ko)
HU (1) HUP0200895A3 (ko)
IL (1) IL145732A0 (ko)
MX (1) MXPA01010109A (ko)
NO (1) NO20014849L (ko)
NZ (1) NZ514661A (ko)
PL (1) PL351898A1 (ko)
RU (1) RU2219172C2 (ko)
TR (1) TR200102908T2 (ko)
WO (1) WO2000059889A1 (ko)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002051441A1 (fr) * 2000-12-26 2002-07-04 Sankyo Company, Limited Compositions medicinales contenant un diuretique et un agent renforçant la resistance a l'insuline
WO2003002550A1 (en) * 2001-06-28 2003-01-09 Dr. Reddy's Research Foundation Dioxalane derivatives and a process for their preparation
WO2003010157A1 (en) * 2001-07-23 2003-02-06 Dr. Reddy's Research Foundation Dioxane derivatives and a process for their preparation
US7067530B2 (en) 2001-07-30 2006-06-27 Novo Nordisk A/S Compounds, their preparation and use
JP2005503377A (ja) * 2001-07-30 2005-02-03 ノボ　ノルディスク　アクティーゼルスカブ 新規ビニルｎ−（２−ベンゾイルフェニル）−ｌ−チロシン誘導体及び抗糖尿病剤等へのそれらの使用
EP1414785A1 (en) * 2001-07-30 2004-05-06 Novo Nordisk A/S Novel vinyl n-(2-benzoylphenyl)-l-tyrosine derivatives and their use as antidiabetics etc
FR2829765A1 (fr) * 2001-09-14 2003-03-21 Lipha Derives imidazolylalkoxylarylalcanoiques leurs applications en therapeutique
SE0104334D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0314079D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0229931D0 (en) 2002-12-21 2003-01-29 Astrazeneca Ab Therapeutic agents
WO2003053938A1 (en) * 2001-12-20 2003-07-03 Novo Nordisk A/S Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten
AU2003207808A1 (en) * 2002-02-21 2003-09-09 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
US8980952B2 (en) * 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
PT2438913T (pt) 2002-03-20 2020-05-27 Us Veterans Affairs Canal de catiões não seletivos em células neurais e compostos que bloqueiam o canal para utilização no tratamento de edema cerebral
AU2003254795A1 (en) * 2002-08-02 2004-02-23 Sankyo Company, Limited Resorcinol derivative
PL213095B1 (pl) 2002-08-08 2013-01-31 Kissei Pharmaceutical Pochodna pirazolu, kompozycja farmaceutyczna, srodek do leczenia lub hamowania choroby i zastosowanie pochodnej pirazolu
ZA200501094B (en) * 2002-08-08 2006-10-25 Kissei Pharmaceutical Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
AR041481A1 (es) * 2002-10-07 2005-05-18 Hoffmann La Roche Derivados de acido arilpropionico-oxazol y su uso como agonistas de ppar
US7384965B2 (en) 2003-01-06 2008-06-10 Eli Lilly And Company Fused heterocyclic derivatives as PPAR modulators
BRPI0407180A (pt) * 2003-02-14 2006-02-07 Lilly Co Eli Composto, composição farmacêutica, métodos para modular um receptor ativado pelo proliferador de peroxissoma, para tratar ou prevenir uma doença ou condição, para diminuir a glicose no sangue em um mamìfero, para tratar ou prevenir diabetes mellitus, doença cardiovascular e sìndrome x em um mamìfero, e, uso de um composto
US7563815B2 (en) * 2003-05-05 2009-07-21 Merck & Co., Inc. Benzamidazoles, compositions containing such compounds and methods of use
GB0314136D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314129D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
WO2006036278A2 (en) * 2004-09-18 2006-04-06 University Of Maryland, Baltimore THERAPEUTIC AGENTS TARGETING THE NCCa-ATP CHANNEL AND METHODS OF USE THEREOF
ATE487484T1 (de) * 2004-09-18 2010-11-15 Univ Maryland Therapeutische mittel zum targeting des nc ca-atp-kanals und verwendungsverfahren dafür
TW200637856A (en) * 2005-01-24 2006-11-01 Sankyo Co Process for producing thiazolidinedion compound and intermediate thereof
KR100811100B1 (ko) * 2006-09-27 2008-03-06 한국생명공학연구원 벤즈아졸 유도체를 유효성분으로 함유하는 대사성 질환예방 및 치료용 약학적 조성물
EP3103451A1 (en) 2007-01-12 2016-12-14 University of Maryland, Baltimore Targetting ncca-atp channel for organ protection following ischemic episode
EP2114160B1 (en) * 2007-02-09 2016-11-16 University of Maryland, Baltimore Antagonists of a non-selective cation channel in neural cells
EP2139330B1 (en) * 2007-03-23 2014-09-24 The Board of Regents of The University of Texas System Methods involving aldose reductase inhibitors
JP5294419B2 (ja) * 2007-04-05 2013-09-18 第一三共株式会社 縮合二環式ヘテロアリール誘導体
EP2167107B1 (en) 2007-06-22 2016-12-14 University of Maryland, Baltimore Inhibitors of ncca-atp channels for therapy
JP2011519916A (ja) * 2008-07-02 2011-07-14 ファーマコステック カンパニー リミテッド アミド誘導体の製造方法
MX2011009244A (es) 2009-03-05 2011-09-26 Daiichi Sankyo Co Ltd Derivado de piridina.
CN102946882B (zh) * 2010-02-02 2016-05-18 格斯有限公司 苯基丙氨酸衍生物及其作为非肽glp-1受体调节剂的用途
WO2011094890A1 (en) * 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
CN104744282A (zh) * 2015-02-17 2015-07-01 南通恒盛精细化工有限公司 一种胰岛素增敏剂的制备工艺
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4942245A (en) 1987-04-20 1990-07-17 Kyorin Pharmaceutical Co., Ltd. Benzimidazole Derivatives
CA2150550A1 (en) 1992-12-01 1994-06-09 Melissa S. Egbertson Fibrinogen receptor antagonists
EP0760658B1 (en) 1994-05-27 2002-11-13 Merck & Co. Inc. Compounds for inhibiting osteoclast-mediated bone resorption
AU702661B2 (en) 1994-06-29 1999-02-25 Smithkline Beecham Corporation Vitronectin receptor antagonists
CZ293016B6 (cs) * 1995-06-01 2004-01-14 Sankyo Company Limited Benzimidazolové deriváty a farmaceutické prostředky s jejich obsahem
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
DE19629817A1 (de) 1996-07-24 1998-01-29 Hoechst Ag Neue Imino-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
CA2277273C (en) 1997-01-17 2008-03-25 Merck & Co., Inc. Integrin antagonists
AU1903799A (en) 1997-12-05 1999-06-28 Eisai Co. Ltd. Compositions and methods for modulating the activity of fibroblast growth factor
AU1120599A (en) * 1998-04-23 1999-03-08 Dr. Reddy's Research Foundation New heterocyclic compounds and their use in medicine, process for their reparation and pharmaceutical compositions containing them
TWI250160B (en) 1999-07-06 2006-03-01 Sankyo Co Crystalline 1-methylcarbapenem compound

Also Published As

Publication number Publication date
HUP0200895A2 (hu) 2002-11-28
AU760163B2 (en) 2003-05-08
MXPA01010109A (es) 2002-06-04
IL145732A0 (en) 2002-07-25
KR20020060067A (ko) 2002-07-16
US6596751B2 (en) 2003-07-22
CA2369871A1 (en) 2000-10-12
CN1208323C (zh) 2005-06-29
NO20014849D0 (no) 2001-10-05
HUP0200895A3 (en) 2002-12-28
EP1167357A1 (en) 2002-01-02
RU2219172C2 (ru) 2003-12-20
US20030069294A1 (en) 2003-04-10
WO2000059889A1 (en) 2000-10-12
NO20014849L (no) 2001-11-27
HK1039939A1 (zh) 2002-05-17
CZ20013593A3 (cs) 2002-03-13
EP1167357A4 (en) 2002-06-05
AU3670700A (en) 2000-10-23
BR0009593A (pt) 2002-06-18
CN1353694A (zh) 2002-06-12
PL351898A1 (en) 2003-06-30
TR200102908T2 (tr) 2002-04-22
US20040002512A1 (en) 2004-01-01

Similar Documents

Publication Publication Date Title
NZ514661A (en) alpha-substituted carboxylic acid derivatives and their use as therapeutic agents in pharmaceutical compositions
CA2159546A1 (en) Cycloalkano-indole and -azaindole derivatives
ATE407668T1 (de) Gamma-aminobuttersäurederivate enthaltende, feste arzneimittel und verfahren zu ihrer herstellung
NZ303251A (en) Use of esters of 5-aminolevulinic acid as photosensitising agents in photochemotherapy
ES2102132T3 (es) Amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
NO20050667L (no) N-substituerte-1H-indol-5-propionsyreforbindelser som PPAR agonister nyttige for behandling av diabetes
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
JP2012140439A (ja) 線維芽細胞活性化タンパクα阻害剤
CA2253997A1 (en) Phosphonic acid-substituted benzazepinone-n-acetic acid derivatives, processes for their preparation and pharmaceutical compositions comprising them
CA2589744A1 (en) Pyrrolinidium derivatives as m3 muscarinic receptors
IL157701A0 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
WO2002085861A8 (en) Imidazolidine compounds and their use as cxcr3 antagonists
MXPA02003495A (es) Derivados de piridinio para el manejo de complicaciones vasculares diabeticas y relacionadas con la edad, proceso para su preparacion, y usos terapeuticos de los mismos.
ES2097162T3 (es) Utilizacion de acidos grasos de cadena corta en alimentacion clinica.
US5330978B1 (en) Phosphonic acid derivatives and use thereof
UA42733C2 (uk) Похідні біснафталіміду та їх фармацевтично прийнятні кислотно-адитивні солі, фармацевтична композиція з цитотоксичною активністю, яка їх містить
US5506264A (en) Zinc tranexamate compounds
CA2005980A1 (en) Benzimidazole derivative with gastric acid inhibitory effect and process for its preparation
GEP20043240B (en) Novel Thiazolidinedione Derivatives as Antidiabetic Agents, Methods for their Production and Pharmaceutical Composition Containing the Same
JPH06511231A (ja) ２−（ピロリジニル−１−メチル）−ピペリジン誘導体およびκ受容体アゴニストとしてのその使用
IE891578L (en) Compounds with central analgesic activity, process for their¹preparation and pharmaceutical compositions containing them
EP1174421A4 (en) 3-AMIDINOBENZENESULFONAMIDE DERIVATIVES, MEDICAL PREPARATIONS CONTAINING IT AND INTERMEDIATE PRODUCTS IN THEIR PRODUCTION
PL371729A1 (en) Piperidine derivative compounds and drugs containing the compounds as the active ingredient
CA2372238A1 (en) Polymorphs of a crystalline azabicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions
CA2133186A1 (en) 3- or 4-glycosyloxybenzopyran derivative and antiallergic agent containing the derivative as active ingredient

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)